Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example.

Leoutsakos JM, Bartlett AL, Forrester SN, Lyketsos CG.

Alzheimers Dement. 2014 Mar;10(2):152-61. doi: 10.1016/j.jalz.2013.05.1776. Epub 2013 Aug 15.

2.

Extended results of the Alzheimer's disease anti-inflammatory prevention trial.

Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group.

Alzheimers Dement. 2011 Jul;7(4):402-11. doi: 10.1016/j.jalz.2010.12.014.

3.

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).

Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group.

Alzheimers Dement. 2013 Nov;9(6):714-23. doi: 10.1016/j.jalz.2012.11.012. Epub 2013 Apr 3.

4.

Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.

Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG; ADAPT Research Team.

Int J Geriatr Psychiatry. 2012 Apr;27(4):364-74. doi: 10.1002/gps.2723. Epub 2011 May 10.

5.

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2013 Jan;34(1):62-72. doi: 10.1016/j.neurobiolaging.2012.03.006. Epub 2012 Apr 13.

6.

Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial.

Fields C, Drye L, Vaidya V, Lyketsos C; ADAPT Research Group.

Am J Geriatr Psychiatry. 2012 Jun;20(6):505-13. doi: 10.1097/JGP.0b013e318227f4da.

7.

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M.

Arch Neurol. 2008 Jul;65(7):896-905. doi: 10.1001/archneur.2008.65.7.nct70006. Epub 2008 May 12.

8.

Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia?

Bregman N, Karni A, Korczyn AD.

Arch Neurol. 2009 Apr;66(4):539-40; author reply 540. doi: 10.1001/archneurol.2009.52. No abstract available.

PMID:
19364945
9.

Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial.

Reckess GZ, Brandt J, Luis CA, Zandi P, Martin B, Breitner JC; ADAPT Research Group.

J Alzheimers Dis. 2013;36(3):433-43. doi: 10.3233/JAD-130113.

10.

Relationship of dementia screening tests with biomarkers of Alzheimer's disease.

Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC.

Brain. 2010 Nov;133(11):3290-300. doi: 10.1093/brain/awq204. Epub 2010 Sep 7.

11.

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Ayutyanont N, Langbaum JB, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, Ward M, Aguirre C, Acosta-Baena N, Madrigal L, Muñoz C, Tirado V, Moreno S, Tariot PN, Lopera F, Reiman EM.

J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927. Review.

12.

A data-driven model of biomarker changes in sporadic Alzheimer's disease.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.

13.

Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.

ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC.

Alzheimers Dement. 2009 Mar;5(2):93-104. doi: 10.1016/j.jalz.2008.09.004.

14.

Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.

ADAPT-FS Research Group.

Alzheimers Dement. 2015 Feb;11(2):216-25.e1. doi: 10.1016/j.jalz.2014.03.009. Epub 2014 Jul 9.

15.

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.

Jaturapatporn D, Isaac MG, McCleery J, Tabet N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD006378. doi: 10.1002/14651858.CD006378.pub2. Review.

PMID:
22336816
16.

Anti-inflammatory drugs fall short in Alzheimer's disease.

[No authors listed]

Nat Med. 2008 Sep;14(9):916. doi: 10.1038/nm0908-916. No abstract available.

PMID:
18776882
17.

NSAIDs and Alzheimer's disease: how far to generalise from trials?

Breitner JC.

Lancet Neurol. 2003 Sep;2(9):527. Review. No abstract available.

PMID:
12941571
18.

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Schneider LS, Kennedy RE, Cutter GR; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 Sep;6(5):367-77. doi: 10.1016/j.jalz.2010.07.004.

19.

Power calculations for clinical trials in Alzheimer's disease.

Ard MC, Edland SD.

J Alzheimers Dis. 2011;26 Suppl 3:369-77. doi: 10.3233/JAD-2011-0062. Review.

20.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk